Bioequivalence in adults does not mean bioequivalence in children

DOSSCHE L.1,2,3, MICHELET R.1,2,3, DE BRUYNE P.1, VAN BOCKLAER J.1,2,3, VERMEULEN A.1,2,3, VAN DE WALLE J.1,2,3
1Department of Paediatric Nephrology, Ghent University Hospital, Ghent, Belgium
2Laboratory of Medical Biochemistry and Clinical Analysis, Department of Bioanalysis, Faculty of Pharmaceutical Sciences, Ghent University, Belgium
3On behalf of the SAFEPEDRUG consortium, http://safepedrug.eu

Introduction

For a new formulation of an existing drug, as well as for generics, one has only to demonstrate pharmacokinetic (PK) bioequivalence with the original formulation to obtain registration. This PK tests are performed in healthy young volunteers, taking for granted that PK follows pharmacodynamics (PD). However, this methodology hardly takes into account potential gender, size, age, maturation specific differences in bioequivalence. FDA and EMA-regulation on pediatric drug research have tried to find a compromise between minimal exposure of children to a pediatric research program, and acquiring minimal PK/PD and safety-data in children to reassure safe prescription of the drug, and therefore do not request bioequivalence studies in the pediatric age.

Aim

The aim of this overview was to question if bioequivalence between different solutions is similar over all populations.

Method

Desmopressin (dDAVP), a synthetic vasopressin analogue, is a level 1, grade A treatment of monosymptomatic enuresis nocturna (MNE). This oligopeptide was studied because of the low biodisponibility with large variation, and existing PK/PD data from previous studies.

Results

Integrating the data of the different studies on different formulations, we observe:
• A higher PD effect for dDAVP lyophilisate (MELT) to tablet, when adjusted with nutrition (Fig. 1 a-b-c (Ref.1))
• A higher PK bioequivalent dose for lyophilisate (MELT) in children than in adults (Fig.2 (Ref.2))
• Compared with previous literature:
  1. The relative bioavailability between the lyophilisate and tablet formulations is probably not the same in children as in adults
  2. Poor correlation between circulating PK and PD-effect (hysteresis-effect)

Conclusion: This overview demonstrates that for an oligopeptide like dDAVP, with a narrow safety-profile, PK/PD bioequivalence of doses within the therapeutic range in children, cannot be extrapolated from adult data. This suggests that minor changes in formulation makes appropriate bioequivalence studies in children mandatory and collection of safety-data required.

References